Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wholesale Business Deteriorating due to War for Market Share: Mr Hamada of Toho HD
May 30, 2011
- Teva to Acquire Majority Stake in Taiyo
May 30, 2011
- Premium for New Drug Development an “Incentive”to Japan Business: Chairman Viehbacher of PhRMA
May 30, 2011
- Teva-Taiyo Strategic Tie-up to Have “No Major Impact”on Sawai: President Sawai
May 30, 2011
- Astellas Completes Acquisition of Perseid
May 30, 2011
- Korosho Approves 2 Class 1 OTC Anti-allergic Eye Drops
May 30, 2011
- Daiichi Sankyo Launches SPRIX Nasal Spray in US
May 30, 2011
- Sanofi-aventis Changes Corporate Name to Sanofi
May 30, 2011
- NanoCarrier's NC-4016 to Obtain Substance Patent in US
May 30, 2011
- Takeda to Acquire Nycomed for 9.6 Bil. Euros
May 30, 2011
- JMA Formally Requests Postponement of Medical, Nursing Fee Revisions
May 30, 2011
- Top-10 Domestic Drug Makers' Sales, Profits Down due to Patent Expirations
May 30, 2011
- “Strict Warning”Issued to MSD for 4 Violations of Fair Promotion Code
May 30, 2011
- MTPC: Sales Up 1.2%, Double-digit Growth in Profits
May 30, 2011
- Asahi Kasei Pharma Obtains Marketing Approval for Flivas in South Korea
May 30, 2011
- DSP: Sales Up 28.1% through Acquisition of Sunovion of US
May 30, 2011
- Eisai's Novel Anticancer Drug Halaven Approved in Switzerland
May 30, 2011
- Iberica HD to Expand Clinical Pharmacology Facilities in the US
May 23, 2011
- NBI Stresses Good Cost-effectiveness of Prazaxa
May 23, 2011
- Fuji Yakuhin: Drugstore Division Sales Up 1.4% in FY2010
May 23, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…